Temozolomide and interferon α2b in metastatic melanoma stage IV

British Journal of Dermatology

Volumn 151, Issue 1, 2004, Pages 91-98

  Richtig, E ^a   Hofmann Wellenhof, R ^a   Pehamberger, H ^b   Forstinger, Ch ^b   Wolff, K ^b   Mischer, P ^c   Raml, J ^c   Fritsch, P ^d   Zelger, B ^d   Ratzinger, G ^d   Koller, J ^e   Lang, A ^b   Konrad, K ^f   Kindermann Glebowski, E ^f   Seeber, A ^f   Steiner, A ^g   Fialla, R ^g   Pachinger, W ^h   Kos, C ^h   Klein, G ⁱ   Kehrer, H ⁱ   Kerl, H ^a   Ulmer, H ^j   Smolle, J ^a   more..

^a UNIVERSITY OF GRAZ   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Hospital of Wels   (Austria)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e University Hospital Salzburg   (Austria)

^f DANUBE HOSPITAL   (Austria)

^g Danube Hospital ^*  (Austria)

^h GENERAL HOSPITAL KLAGENFURT   (Austria)

ⁱ KH Elisabethinen   (Austria)

^j UNIVERSITY OF INNSBRUCK   (Austria)

more..

Author keywords

Interferon 2b; Metastatic malignant melanoma; Temozolomide

Indexed keywords

ALPHA2B INTERFERON; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEADACHE; HUMAN; LEUKOPENIA; LIVER FUNCTION; MALE; MELANOMA; METASTASIS; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; REMISSION; SEPSIS; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON ALFA-2B; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 4043079891     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2004.06019.x     Document Type: Article

References (48)

1. Rieger E, Soyer HP, Kofler R et al. Zur Epidemiologie des malignen Melanoms an der Grazer Hautklinik von 1970-88. In: Das Maligne Melanom (Waclawiczek HW, ed.). Berlin: Springer-Verlag, 1991: 43-7.
2. Santigli E. Die steirische Wohnbevölkerung. In: Gesundheitsbericht 2000 für die Steiermark (Piribauer F, ed.). Graz: Amt der Steiermärkischen Landesregierung. 2000; 28.
3. Balch Ch, Buzaid A, Atkins M et al. A new American Joint Committee on Cancer Staging System for Cutaneous Melanoma. Cancer 2000; 88: 1484-91.
4. Sirott MN, Bajorin DF, Wong GYC et al. Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer 1993; 72: 3091-8.
5. Manola J, Atkins M, Ibrahim J, Kirkwood J. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group Trials. J Clin Oncol 2000; 18: 3782-93.
6. Becker JC, Kämpgen E, Bröcker EB. Klassische Chemotherapie des metastasierenden Melanoms. Z Hautkr 2000; 9: 553-8.
7. Wendtner CM, Hallek M, Schmid-Wendtner MH. Medikamentöse Therapie bei Fernmetastasierung. In: Empfehlungen zur Diagnostik, Therapie und Nachsorge maligner Melanome, Tumorzentrum München (Volkenandt M, Plewig G. eds), 5th edn. Munich: Zugschwerdt, 2000; 65-71.
8. Falkson CI, Falkson G, Falkson HC. Improved results with the addition of interferon alpha-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 1991; 9: 1403-8.
9. Chapman PB, Einhorn LH, Meyers ML et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17: 2745-51.
10. Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 2000; 19: 21-34.
11. Tilgen W, Uhl K, Bröcker EB. Palliative Therapie des malignen Melanoms. In: Dermatologische Onkologie (Garbe C, Dummer R, Kaufmann R, Tilgen W, eds). Berlin: Springer-Verlag, 1997: 369-86.
12. Walsh P, Gibbs P, Gonzalez R. Newer strategies for effective evaluation of primary melanoma and treatment of stage III and IV disease. J Am Acad Dermatol 2000; 42: 480-9.
13. Jelic S, Babovic N, Stamatovic L et al. Vinblastin-carboplatin for metastatic cutaneous melanoma as first-line chemotherapy and in dacarbazine failures: a single-center study. Med Oncol 2001; 18: 189-95.
14. Chiarion-Sileni V, Nortilli R, Aversa SM et al. Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. Melanoma Res 2001; 11: 189-96.
15. Güven K, Kittler H, Wolff K, Pehamberger H. Cisplatin and carboplatin combination as second-line chemotherapy in dacarbazine-resistant melanoma patients. Melanoma Res 2001; 11: 411-15.
16. Nathan FE, Berd D, Sato T, Mastrangelo MJ. Paclitaxel and tamoxifen: an active regimen for patients with metastatic melanoma. Cancer 2000; 88: 79-87.
17. Feun LG, Savaraj N, Hurley J et al. A clinical trial of intravenous vinorelbine tartrate plus tamoxifen in the treatment of patients with advanced malignant melanoma. Cancer 2000; 88: 584-8.
18. McClay EF, McClay MT, Monroe L et al. A phase II study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma. Melanoma Res 2001; 11: 309-13.
19. Propper DJ, Braybrooke JP, Levitt NC et al. Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine. Br J Cancer 2000; 82: 1759-63.
20. Stevens MF, Hickman JA, Stone R et al. Antitumour imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl) imidazo (5,1-d)-1,2,3,5-tetrazin-4(3H)-one, a novel broad spectrum antitumour agent. J Med Chem 1984; 27: 196-201.
21. Newlands ES, Stevens MF, Wedge SR et al. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997; 23: 35-61.
22. Tsang LLH, Quarterman CP, Gescher A, Slack JA. Comparison of the cytotoxicity in vitro of temozolomide and dacarbacine, pro-drugs of 3-methyl-(triazen-1-yl) imidazole-4-carboxamide. Cancer Chemother Pharmacol 1991; 27: 342-6.
23. Agarwala SS, Kirkwood JM. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 2000; 5: 144-51.
24. Middleton MR, Grob JJ, Aaronson N et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18: 158-66.
25. Bafaloukos D, Gogas H, Georgoulias V et al. Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group. J Clin Oncol 2002; 20: 420-5.
26. Bleehen NM, Newlands ES, Lee SM et al. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 1995; 13: 910-13.
27. Hwu WJ. New approaches in the treatment of metastatic melanoma: thalidomide and temozolomide. Oncology 2000; 12 (Suppl. 13): S25-8.
28. Newland ES, Blackledge GR, Slack JA et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 1992; 65: 287-91.
29. Thomson DB, Adena M, McLeod GR et al. Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. Melanoma Res 1993; 3: 133-8.
30. Bajetta E, Di-Leo A, Zampino MG et al. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol 1994; 12: 806-11.
31. Huncharek M, Caubet JF, McGarry R. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 2001; 11: 75-81.
32. Kirkwood JM, Agarwala SS, Diaz B et al. Phase I study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma. Presented at the 33rd Annual Meeting of the American Society of Clinical Oncology. Denver, Colorado, 17-20 May 1997.
33. Agarwala SS, Kirkwood JM. Temozolomide in combination with interferon α-2b in patients with metastatic melanoma. Cancer 2003; 97: 121-7.
34. Fischer B, Knop J, Enk AH. Erfahrungen mit der Therapie des metastasierten malignen Melanoms im Stadium IV mittels Polychemotherapie nach dem 'Legha-Protokoll'. Hautarzt 2002; 53: 393-9.
35. Dillman RO, Soori G, Wiemann MC et al. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11. Cancer Biother Radiopharm 2000; 15: 487-94.
36. Daponte A, Ascierto PA, Gravina A et al. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group. Cancer 2000; 89: 2630-6.
37. Eton O, Legha SS, Bedikian AY et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002; 20: 2045-52.
38. Balch CM, Soong SJ, Murad TM et al. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1983; 1: 126-34.
39. Pehamberger H, Soyer HP, Steiner A et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. J Clin Oncol 1998; 16: 1425-9.
40. Kirkwood JM, Strawderman MH, Ernstoff MS et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 1996; 14: 7-17.
41. Kirkwood JM, Ibrahim JG, Sondak VK et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup Trial E1690/S9111/C9190. J Clin Oncol 2000; 18: 2444-58.
42. Grob JJ, Dreno B, de la Salmoniere P et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. Lancet 1998; 351: 1905-10.
43. Russell-Jones R. Interferon-alpha therapy for melanoma. Clin Exp Dermatol 2000; 25: 1-6.
44. Garbe C, Krasagakis K, Zouboulis CC et al. Antitumor activities of interferon alpha, beta and gamma and their combinations on human melanoma cells in vitro: changes in proliferation, melanin synthesis and immunophenotype. J Invest Dermatol 1990; 95 (Suppl. 6): S231-7.
45. Hauschild A, Hinrichsen H, Christophers E. Nebenwirkungen der Interferontherapie und deren Management. Hautarzt 2000; 51: 793-803.
46. Frick S, Lischner S, Rosien F et al. Temozolomid als Therapieoption bei Patienten mit fernmetastasiertem Melanom und ungünstiger Prognose. Hautarzt 2002; 53: 659-65.
47. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 1995; 181: 193-201.
48. Garbe C, Schaumburg-Lever G. Klinik und Histologie des malignen Melanoms. In: Dermatologische Onkologie (Garbe C, Dummer R, Kaufmann R, Tilgen W, eds), Berlin; Springer-Verlag, 1997: 247-70